Home About Us
AIMS & SCOPES
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) launched in 2013, is designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians/physicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers. The Journal’s content includes peer reviewed research, commentaries, news features, discussions, editorials and blogs on topics relevant to a broad international readership. The Journal also offers a knowledge center (called ADC University) offering the latest and most relevant information about Antibody-drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments. The purpose of the Journal is to present this information in an understandable and a useful format for all stakeholders.
Editorial Office | 4960 South Gilbert Rd, Suite 1-286, Chandler, AZ 85249 (USA)
PUBLISHING TEAM
PUBLISHER
Sunvalley Communication is a full-service, high science marketing, medical education and marketing communications agency, specializing in brand building, creative, editorial and communication strategies and publication planning for medical, pharmaceutical and life science companies.
FOUNDING SPONSOR
Site Sponsor
CONTENT PARTNERS
DIRECTORY PARTNERS
DISCLAIMER
ADC Review, Journal of Antibody-drug Conjugates is a peer reviewed journal with news, information and education sections. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a specific medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication.
